Christophe Caux

List of Publications by Year in Descending Order

126 papers	18,654 citations	57 h-index	136 g-index
149 ext. papers	20,563 ext. citations	8.3 avg, IF	6.1 L-index

#	Paper	IF	Citations
126	Identification of shared tumor epitopes from endogenous retroviruses inducing high-avidity cytotoxic T cells for cancer immunotherapy.. *Science Advances*, **2022**, 8, eabj3671	14.3	4
125	Recruitment and Expansion of Tregs Cells in the Tumor Environment-How to Target Them?. *Cancers* , **2021**, 13,	6.6	13
124	Type 1 conventional dendritic cells and interferons are required for spontaneous CD4 and CD8 T-cell protective responses to breast cancer. *Clinical and Translational Immunology*, **2021**, 10, e1305	6.8	8
123	Design and methods of a national, multicenter, randomized and controlled trial to assess the efficacy of a physical activity program to improve health-related quality of life and reduce fatigue in women with metastatic breast cancer: ABLE02 trial. *BMC Cancer*, **2020**, 20, 622	4.8	3
122	CD163 tumor-associated macrophage accumulation in breast cancer patients reflects both local differentiation signals and systemic skewing of monocytes. *Clinical and Translational Immunology*, **2020**, 9, e1108	6.8	26
121	Repurposing infectious disease vaccines for intratumoral immunotherapy **2020**, 8,		13
120	IFN-III is selectively produced by cDC1 and predicts good clinical outcome in breast cancer. *Science Immunology*, **2020**, 5,	28	42
119	Neutrophil Heterogeneity in Cancer: From Biology to Therapies. *Frontiers in Immunology*, **2019**, 10, 2155	8.4	74
118	Cold Tumors: A Therapeutic Challenge for Immunotherapy. *Frontiers in Immunology*, **2019**, 10, 168	8.4	338
117	Targeting Adenosine in Cancer Immunotherapy to Enhance T-Cell Function. *Frontiers in Immunology* , **2019**, 10, 925	8.4	159
116	A novel combination of chemotherapy and immunotherapy controls tumor growth in mice with a human immune system. *OncoImmunology*, **2019**, 8, 1596005	7.2	12
115	Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines? **2019**, 7, 85		84
114	Human Tumor-Infiltrating Dendritic Cells: From in Situ Visualization to High-Dimensional Analyses. *Cancers*, **2019**, 11,	6.6	17
113	Repurposing rotavirus vaccines for intratumoral immunotherapy can overcome resistance to immune checkpoint blockade. *Science Translational Medicine*, **2019**, 11,	17.5	34
112	Methotrexate Restores CD73 Expression on Th1.17 in Rheumatoid Arthritis and Psoriatic Arthritis Patients and May Contribute to Its Anti-Inflammatory Effect through Ado Production. *Journal of Clinical Medicine*, **2019**, 8,	5.1	4
111	CD73 expression in normal and pathological human hepatobiliopancreatic tissues. *Cancer Immunology, Immunotherapy*, **2019**, 68, 467-478	7.4	20
110	Neoepitopes-based vaccines: challenges and perspectives. *European Journal of Cancer*, **2019**, 108, 55-60	7.5	11

109	Genetic alterations and tumor immune attack in Yo paraneoplastic cerebellar degeneration. *Acta Neuropathologica*, **2018**, 135, 569-579	14.3	43
108	Autocrine Adenosine Regulates Tumor Polyfunctional CD73CD4 Effector T Cells Devoid of Immune Checkpoints. *Cancer Research*, **2018**, 78, 3604-3618	10.1	40
107	CD73 expression and clinical significance in human metastatic melanoma. *Oncotarget*, **2018**, 9, 26659-26669	5.3	31
106	MDR1 in immunity: friend or foe?. *OncoImmunology*, **2018**, 7, e1499388	7.2	17
105	MAVS deficiency induces gut dysbiotic microbiota conferring a proallergic phenotype. *Proceedings of the National Academy of Sciences of the United States of America*, **2018**, 115, 10404-10409	11.5	10
104	Description of the immune microenvironment of chondrosarcoma and contribution to progression. *OncoImmunology*, **2017**, 6, e1265716	7.2	15
103	BAD-LAMP controls TLR9 trafficking and signalling in human plasmacytoid dendritic cells. *Nature Communications*, **2017**, 8, 913	17.4	34
102	Emerging Role of the Unfolded Protein Response in Tumor Immunosurveillance. *Trends in Cancer*, **2017**, 3, 491-505	12.5	23
101	Cancer-Associated Tertiary Lymphoid Structures, from Basic Knowledge Toward Therapeutic Target in Clinic. *Resistance To Targeted Anti-cancer Therapeutics*, **2016**, 99-125	0.3	
100	Follicular B Lymphomas Generate Regulatory T Cells via the ICOS/ICOSL Pathway and Are Susceptible to Treatment by Anti-ICOS/ICOSL Therapy. *Cancer Research*, **2016**, 76, 4648-60	10.1	46
99	A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage. *OncoImmunology*, **2016**, 5, e1091146	7.2	38
98	TGF-□nhibits the activation and functions of NK cells by repressing the mTOR pathway. *Science Signaling*, **2016**, 9, ra19	8.8	297
97	Abstract 2320: CD70 immune checkpoint ligand is associated with the epithelial-to-mesenchymal transition in non-small cell lung cancer **2016**,		2
96	Abstract 2344: Discovery and characterization of new original blocking antibodies targeting the CD73 immune checkpoint for cancer immunotherapy **2016**,		2
95	A Milestone Review on How Macrophages Affect Tumor Growth. *Cancer Research*, **2016**, 76, 6439-6442	10.1	53
94	Paradigm shift in oncology: targeting the immune system rather than cancer cells. *Mutagenesis*, **2015**, 30, 205-11	2.8	36
93	PRKDC mutations associated with immunodeficiency, granuloma, and autoimmune regulator-dependent autoimmunity. *Journal of Allergy and Clinical Immunology*, **2015**, 135, 1578-88.e5	11.5	52
92	Human natural killer cells promote cross-presentation of tumor cell-derived antigens by dendritic cells. *International Journal of Cancer*, **2015**, 136, 1085-94	7.5	48

91	In Vitro and In Vivo Comparison of Lymphocytes Transduced with a Human CD16 or with a Chimeric Antigen Receptor Reveals Potential Off-Target Interactions due to the IgG2 CH2-CH3 CAR-Spacer. *Journal of Immunology Research*, **2015**, 2015, 482089	4.5	15
90	Breast Cancer Cell-Derived GM-CSF Licenses Regulatory Th2 Induction by Plasmacytoid Predendritic Cells in Aggressive Disease Subtypes. *Cancer Research*, **2015**, 75, 2775-87	10.1	38
89	Disequilibrium of BMP2 levels in the breast stem cell niche launches epithelial transformation by overamplifying BMPR1B cell response. *Stem Cell Reports*, **2015**, 4, 239-54	8	40
88	Follicular Lymphoma B Cells Generate Functional Regulatory T Cells Via ICOS/ICOSL Pathway and Are Inhibited By Intratumoral Tregs. *Blood*, **2015**, 126, 5018-5018	2.2	
87	Intratumoral immunization: a new paradigm for cancer therapy. *Clinical Cancer Research*, **2014**, 20, 1747-56	10.9	153
86	TLR9 transcriptional regulation in response to double-stranded DNA viruses. *Journal of Immunology* , **2014**, 193, 3398-408	5.3	7
85	Human XCR1+ dendritic cells derived in vitro from CD34+ progenitors closely resemble blood dendritic cells, including their adjuvant responsiveness, contrary to monocyte-derived dendritic cells. *Journal of Immunology*, **2014**, 193, 1622-35	5.3	90
84	ELYPSE-7: A randomized, placebo-controlled, phase 2a study evaluating the impact of IL-7 on CD4 count, hematological toxicity, and tumor progressionin metastatic breast cancer (MBC) patients (pts).. *Journal of Clinical Oncology*, **2014**, 32, 3033-3033	2.2	
83	Autocrine role for Gas6 with Tyro3 and Axl in leiomyosarcomas. *Targeted Oncology*, **2013**, 8, 261-9	5	9
82	Breast cancer-derived transforming growth factor-β and tumor necrosis factor-α compromise interferon-α production by tumor-associated plasmacytoid dendritic cells. *International Journal of Cancer*, **2013**, 133, 771-8	7.5	65
81	Tumor promotion by intratumoral plasmacytoid dendritic cells is reversed by TLR7 ligand treatment. *Cancer Research*, **2013**, 73, 4629-40	10.1	132
80	Patients with metastatic breast cancer leading to CD4+ T cell lymphopaenia have poor outcome. *European Journal of Cancer*, **2013**, 49, 1673-82	7.5	30
79	CD4 lymphopenia to identify end-of-life metastatic cancer patients. *European Journal of Cancer*, **2013**, 49, 1080-9	7.5	25
78	ICOS is associated with poor prognosis in breast cancer as it promotes the amplification of immunosuppressive CD4 T cells by plasmacytoid dendritic cells. *OncoImmunology*, **2013**, 2, e23185	7.2	43
77	Plasmacytoid dendritic cells deficient in IFN-α production promote the amplification of FOXP3 regulatory T cells and are associated with poor prognosis in breast cancer patients. *OncoImmunology*, **2013**, 2, e22338	7.2	39
76	Immunobiology. Combined targeted and immunotherapy: the future of personalized medicine. *Blood*, **2012**, 120, 4454-5	2.2	6
75	Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. *Cancer Research*, **2012**, 72, 5188-97	10.1	216
74	Targeting pattern recognition receptors in cancer immunotherapy. *Targeted Oncology*, **2012**, 7, 29-54	5	100

73	Targeting regulatory T cells. *Targeted Oncology*, **2012**, 7, 15-28	5	57
72	Plasmacytoid dendritic cells infiltrating ovarian cancer are associated with poor prognosis. *OncoImmunology*, **2012**, 1, 380-382	7.2	85
71	Innate immune recognition of breast tumor cells mediates CCL22 secretion favoring Treg recruitment within tumor environment. *OncoImmunology*, **2012**, 1, 759-761	7.2	19
70	ICOS-ligand expression on plasmacytoid dendritic cells supports breast cancer progression by promoting the accumulation of immunosuppressive CD4+ T cells. *Cancer Research*, **2012**, 72, 6130-41	10.1	134
69	Lymphopenia combined with low TCR diversity (divpenia) predicts poor overall survival in metastatic breast cancer patients. *OncoImmunology*, **2012**, 1, 432-440	7.2	67
68	CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues. *Blood*, **2011**, 118, 5130-40	2.2	39
67	Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer. *BMC Cancer*, **2011**, 11, 213	4.8	23
66	Quantitative and functional alterations of plasmacytoid dendritic cells contribute to immune tolerance in ovarian cancer. *Cancer Research*, **2011**, 71, 5423-34	10.1	140
65	CpG promotes cross-presentation of dead cell-associated antigens by pre-CD8□ dendritic cells [corrected]. *Journal of Immunology*, **2011**, 186, 1503-11	5.3	44
64	Early detection of tumor cells by innate immune cells leads to T(reg) recruitment through CCL22 production by tumor cells. *Cancer Research*, **2011**, 71, 6143-52	10.1	82
63	TLR3 and Rig-like receptor on myeloid dendritic cells and Rig-like receptor on human NK cells are both mandatory for production of IFN-gamma in response to double-stranded RNA. *Journal of Immunology*, **2010**, 185, 2080-8	5.3	75
62	Impaired Toll-like receptor 7 and 9 signaling: from chronic viral infections to cancer. *Trends in Immunology*, **2010**, 31, 391-7	14.4	86
61	Differences in tumor regulatory T-cell localization and activation status impact patient outcome. *Cancer Research*, **2009**, 69, 7895-8	10.1	91
60	High diversity of the immune repertoire in humanized NOD.SCID.gamma c-/- mice. *European Journal of Immunology*, **2009**, 39, 2136-45	6.1	49
59	Regulatory T cells recruited through CCL22/CCR4 are selectively activated in lymphoid infiltrates surrounding primary breast tumors and lead to an adverse clinical outcome. *Cancer Research*, **2009**, 69, 2000-9	10.1	489
58	Cell proliferation and survival induced by Toll-like receptors is antagonized by type I IFNs. *Proceedings of the National Academy of Sciences of the United States of America*, **2007**, 104, 8047-52	11.5	62
57	Human Langerhans cells express a specific TLR profile and differentially respond to viruses and Gram-positive bacteria. *Journal of Immunology*, **2006**, 177, 7959-67	5.3	210
56	The class 6 semaphorin SEMA6A is induced by interferon-gamma and defines an activation status of langerhans cells observed in pathological situations. *American Journal of Pathology*, **2006**, 168, 453-65	5.8	19

55	Dendritic cells rapidly recruited into epithelial tissues via CCR6/CCL20 are responsible for CD8+ T cell crosspriming in vivo. *Immunity*, **2006**, 24, 191-201	32.3	280
54	Critical role of ITIM-bearing FcgammaR on DCs in the capture and presentation of native antigen to B cells. *Immunity*, **2005**, 23, 463-4	32.3	7
53	A type I interferon autocrine-paracrine loop is involved in Toll-like receptor-induced interleukin-12p70 secretion by dendritic cells. *Journal of Experimental Medicine*, **2005**, 201, 1435-46	16.6	433
52	Fc receptor gamma-chain activation via hOSCAR induces survival and maturation of dendritic cells and modulates Toll-like receptor responses. *Blood*, **2005**, 105, 3623-32	2.2	33
51	MIP-3alpha/CCL20 in renal transplantation and its possible involvement as dendritic cell chemoattractant in allograft rejection. *American Journal of Transplantation*, **2005**, 5, 2114-25	8.7	31
50	Recognition of double-stranded RNA by human toll-like receptor 3 and downstream receptor signaling requires multimerization and an acidic pH. *Journal of Biological Chemistry*, **2005**, 280, 38133-45	5.4	192
49	Distinct and overlapping roles of interleukin-10 and CD25+ regulatory T cells in the inhibition of antitumor CD8 T-cell responses. *Cancer Research*, **2005**, 65, 8479-86	10.1	62
48	CCL1-CCR8 interactions: an axis mediating the recruitment of T cells and Langerhans-type dendritic cells to sites of atopic skin inflammation. *Journal of Immunology*, **2005**, 174, 5082-91	5.3	162
47	Virus overrides the propensity of human CD40L-activated plasmacytoid dendritic cells to produce Th2 mediators through synergistic induction of IFN-{gamma} and Th1 chemokine production. *Journal of Leukocyte Biology*, **2005**, 78, 954-66	6.5	24
46	Breast carcinoma cells promote the differentiation of CD34+ progenitors towards 2 different subpopulations of dendritic cells with CD1a(high)CD86(-)Langerin- and CD1a(+)CD86(+)Langerin+ phenotypes. *International Journal of Cancer*, **2004**, 110, 710-20	7.5	44
45	Human dendritic cells express neuronal Eph receptor tyrosine kinases: role of EphA2 in regulating adhesion to fibronectin. *Blood*, **2003**, 102, 4431-40	2.2	53
44	The inducible CXCR3 ligands control plasmacytoid dendritic cell responsiveness to the constitutive chemokine stromal cell-derived factor 1 (SDF-1)/CXCL12. *Journal of Experimental Medicine*, **2003**, 198, 823-30	16.6	199
43	Pharmacological analysis of calcium responses mediated by the human A3 adenosine receptor in monocyte-derived dendritic cells and recombinant cells. *Molecular Pharmacology*, **2003**, 63, 342-50	4.3	54
42	Sequential involvement of CCR2 and CCR6 ligands for immature dendritic cell recruitment: possible role at inflamed epithelial surfaces. *European Journal of Immunology*, **2002**, 32, 231-42	6.1	140
41	Tumour escape from immune surveillance through dendritic cell inactivation. *Seminars in Cancer Biology*, **2002**, 12, 33-42	12.7	190
40	Corticosteroids prevent generation of CD34+-derived dermal dendritic cells but do not inhibit Langerhans cell development. *Journal of Immunology*, **2002**, 168, 6181-8	5.3	62
39	Reversal of tumor-induced dendritic cell paralysis by CpG immunostimulatory oligonucleotide and anti-interleukin 10 receptor antibody. *Journal of Experimental Medicine*, **2002**, 196, 541-9	16.6	296
38	Isolation and propagation of human dendritic cells. *Methods in Microbiology*, **2002**, 32, 591-620	2.8	

37	Regulation of dendritic cell recruitment by chemokines. *Transplantation*, **2002**, 73, S7-11	1.8	111
36	Chemokines in cancer. *Cytokine and Growth Factor Reviews*, **2002**, 13, 143-54	17.9	287
35	Expression of macrophage inflammatory protein-3alpha, stromal cell-derived factor-1, and B-cell-attracting chemokine-1 identifies the tonsil crypt as an attractive site for B cells. *Blood*, **2001**, 97, 3992-4	2.2	37
34	IL-10 induces CCR6 expression during Langerhans cell development while IL-4 and IFN-gamma suppress it. *Journal of Immunology*, **2001**, 167, 5594-602	5.3	37
33	Propagation of human dendritic cells in vitro. *Methods in Molecular Medicine*, **2001**, 64, 257-73		
32	Antigen uptake by dendritic cells. *Methods in Molecular Medicine*, **2001**, 64, 369-76		4
31	Human thymus contains IFN-alpha-producing CD11c(-), myeloid CD11c(+), and mature interdigitating dendritic cells. *Journal of Clinical Investigation*, **2001**, 107, 835-44	15.9	148
30	Human thymus contains IFN-□producing CD11c□myeloid CD11c+, and mature interdigitating dendritic cells. *Journal of Clinical Investigation*, **2001**, 108, 1237-1237	15.9	2
29	B cells **2001**, 255-261		
28	Immunobiology of dendritic cells. *Annual Review of Immunology*, **2000**, 18, 767-811	34.7	5321
27	Dendritic cell biology and regulation of dendritic cell trafficking by chemokines. *Seminars in Immunopathology*, **2000**, 22, 345-69		242
26	Antitumor effects of the mouse chemokine 6Ckine/SLC through angiostatic and immunological mechanisms. *Journal of Immunology*, **2000**, 165, 1992-2000	5.3	131
25	Macrophage inflammatory protein 3alpha is expressed at inflamed epithelial surfaces and is the most potent chemokine known in attracting Langerhans cell precursors. *Journal of Experimental Medicine*, **2000**, 192, 705-18	16.6	329
24	Up-regulation of macrophage inflammatory protein-3 alpha/CCL20 and CC chemokine receptor 6 in psoriasis. *Journal of Immunology*, **2000**, 164, 6621-32	5.3	454
23	Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules. *Immunity*, **2000**, 12, 71-81	32.3	757
22	The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. *European Journal of Immunology*, **1999**, 29, 2695-704	6.1	233
21	Respective involvement of TGF-beta and IL-4 in the development of Langerhans cells and non-Langerhans dendritic cells from CD34+ progenitors. *Journal of Leukocyte Biology*, **1999**, 66, 781-91	6.5	110
20	Dendritic cells directly modulate B cell growth and differentiation. *Journal of Leukocyte Biology*, **1999**, 66, 224-30	6.5	107

19	Regulation of dendritic cell trafficking: a process that involves the participation of selective chemokines. *Journal of Leukocyte Biology*, **1999**, 66, 252-62	6.5	199
18	Selective recruitment of immature and mature dendritic cells by distinct chemokines expressed in different anatomic sites. *Journal of Experimental Medicine*, **1998**, 188, 373-86	16.6	1196
17	Human dendritic cells skew isotype switching of CD40-activated naive B cells towards IgA1 and IgA2. *Journal of Experimental Medicine*, **1997**, 185, 1909-18	16.6	209
16	CCR6, a CC chemokine receptor that interacts with macrophage inflammatory protein 3alpha and is highly expressed in human dendritic cells. *Journal of Experimental Medicine*, **1997**, 186, 837-44	16.6	325
15	Dendritic cells enhance growth and differentiation of CD40-activated B lymphocytes. *Journal of Experimental Medicine*, **1997**, 185, 941-51	16.6	264
14	Measles virus infects human dendritic cells and blocks their allostimulatory properties for CD4+ T cells. *Journal of Experimental Medicine*, **1997**, 186, 801-12	16.6	242
13	CD34+ Hematopoietic Progenitors From Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to Granulocyte-Macrophage Colony-Stimulating Factor Plus Tumor Necrosis Factor □II. Functional Analysis. *Blood*, **1997**, 90, 1458-1470	2.2	372
12	Dendritic cell development: multiple pathways to nature□s adjuvants. *Stem Cells*, **1997**, 15, 409-19	5.8	182
11	Identification and analysis of a novel member of the ubiquitin family expressed in dendritic cells and mature B cells. *European Journal of Immunology*, **1997**, 27, 2471-7	6.1	85
10	CD34+ Hematopoietic Progenitors From Human Cord Blood Differentiate Along Two Independent Dendritic Cell Pathways in Response to Granulocyte-Macrophage Colony-Stimulating Factor Plus Tumor Necrosis Factor □II. Functional Analysis. *Blood*, **1997**, 90, 1458-1470	2.2	40
9	Human dendritic/Langerhans cells control growth and differentiation of CD40 activated B cells. *Advances in Experimental Medicine and Biology*, **1997**, 417, 329-34	3.6	5
8	Infection of human dendritic cells by measles virus induces immune suppression. *Advances in Experimental Medicine and Biology*, **1997**, 417, 421-3	3.6	6
7	In Vitro Regulation of Dendritic Cell Development and Function. *Blood Cell Biochemistry*, **1996**, 263-301		17
6	Recent advances in the study of dendritic cells and follicular dendritic cells. *Trends in Immunology*, **1995**, 16, 2-4		168
5	Inhibitory effect of IL-10 on human Langerhans cell antigen presenting function. *Advances in Experimental Medicine and Biology*, **1995**, 378, 359-61	3.6	3
4	Activation of primary allogeneic CD8+ T cells by dendritic cells generated in vitro from CD34+ cord blood progenitor cells. *Advances in Experimental Medicine and Biology*, **1995**, 378, 371-4	3.6	5
3	Human dendritic cells enhance growth and differentiation of CD40 activated B cells. *Advances in Experimental Medicine and Biology*, **1995**, 378, 397-9	3.6	4
2	Interleukin 10 inhibits T cell alloreaction induced by human dendritic cells. *International Immunology*, **1994**, 6, 1177-85	4.9	176

1	Interleukin-10 inhibits the primary allogeneic T cell response to human epidermal Langerhans cells. *European Journal of Immunology*, **1994**, 24, 884-91	6.1	124